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Abstract
Background: The aim of this study was to investigate the relationship between prior Anisakis infections and upper
gastrointestinal bleeding (UGIB), and its interaction with non-steroidal anti-inflammatory drug (NSAID) intake.
Methods/Principal Findings: We conducted a hospital-based case-control study covering 215 UGIB cases and 650 controls.
Odds ratios (ORs) with their confidence intervals (95% CIs) were calculated, as well as the ratio of the combined effects to
the sum of the separate effects of Anisakis allergic sensitization and NSAIDs intake. Prior Anisakis infections were revealed by
the presence of anti-Anisakis IgE antibodies specific to the recombinant Ani s 1 and Ani s 7 allergens used as the targets in
indirect ELISA. Prior Anisakis infections (OR 1.74 [95% CI: 1.10 to 2.75]) and the intake of NSAIDs (OR 6.63 [95% CI: 4.21 to
10.43]) increased the risk of bleeding. Simultaneous NSAIDs intake and Anisakis allergic sensitization increased the risk of
UGIB 14-fold (OR=14.46 [95% CI: 6.08 to 34.40]). This interaction was additive, with a synergistic index of 3.01 (95% CI: 1.18–
7.71).
Conclusions: Prior Anisakis infection is an independent risk factor for UGIB, and the joint effect with NSAIDs is 3 times higher
than the sum of their individual effects.
Citation: Ubeira FM, Anado ´n AM, Salgado A, Carvajal A, Ortega S, et al. (2011) Synergism between Prior Anisakis simplex Infections and Intake of NSAIDs, on the
Risk of Upper Digestive Bleeding: A Case-Control Study. PLoS Negl Trop Dis 5(6): e1214. doi:10.1371/journal.pntd.0001214
Editor: Helton da Costa Santiago, National Institutes of Health, United States of America
Received October 14, 2010; Accepted May 11, 2011; Published June 28, 2011
Copyright:  2011 Ubeira et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was supported by grants PI021512, PI021364, PI020661, PI021572 (Health Research Fund /Fondo de Investigacio ´n Sanitaria), SAF2002-04057
(Ministry of Health and Consumer Affairs, Spain), PGIDIT03PXIC20806PN (Galician Regional Authority, Spain) and 02/1572 (Basque Regional Authority, Spain). The
funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: adolfo.figueiras@usc.es
Introduction
Upper gastrointestinal bleeding (UGIB) is a relatively frequent and
potentially lethal multicausal medical emergency [1]. Gastric and
duodenal ulcers are a major cause of UGIB, and bleeding from these
lesions is frequently related to intake of non-steroidal anti-inflammatory
drugs (NSAIDs) [2]. In countries where Anisakis infections are frequent,
acute infections by this parasite may also provoke UGIB [3].
Anisakiasis is a worldwide re-emerging disease produced by the
consumption of raw, lightly cooked, smoked or marinated fish
containing the infective larvae of the Anisakis genus [4,5]. Most
human cases of anisakiasis have been reported in Japan [6,7], but
there has been an increase in the frequency of reports of Anisakis
infections in other parts of the world, such as Europe [8,9], the
USA, [10,11] and Canada [12].
Depending on the site of infection and the predominant clinical
symptoms, acute infections by Anisakis can be classified as gastric
anisakiasis, gastro-allergic anisakiasis, and intestinal anisakiasis. In
gastric and intestinal anisakiasis, severe gastric or abdominal
symptoms predominate, while in gastro-allergic anisakiasis, allergic
symptoms ranging from mild urticaria to anaphylactic shock are
more important [13,14]. However, recent evidence from seroep-
idemiologic studies undertaken in Spain indicates that the great
majority of human cases of anisakiasis are asymptomatic, and that
the prevalence of disease in different Spanish regions may range
from a minimum of 0.4% [5] to more than 10% of the population
[15,16].
In comparison with the healthy population, a high seropreva-
lence of anti-Anisakis antibodies has been reported in patients with
GI bleeding [17]. However, the relevance of prior Anisakis
infections as a risk factor for UGIB and its possible interaction
with NSAID intake have never been investigated. We now report
the results of a case–control study, which sought to determine the
risk of UGIB associated with prior Anisakis simplex infections and
any potential interaction with NSAID intake.
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Patients
We based our study on data provided by a wider, multicenter,
incident case-control study, which sought to analyze the influence
of environmental and genetic risk factors on UGIB (primary
study). Three Spanish hospitals (Complejo Hospitalario Universi-
tario de Santiago de Compostela, Galicia; Hospital Clı ´nico
Universitario de Valladolid, Castilla-Leo ´n; and Hospitales de
Galdakao-Usansolo/Basurto, Basque Country) that had stored
serum samples for Anisakis determinations were included in the
study. We defined cases as any patient admitted in the period
2003–2006 with primary diagnosis of UGIB and subsequent
endoscopic diagnosis of duodenal or gastric ulcer, acute lesions of
the gastric mucosa, erosive duodenitis or mixed lesions. To ensure
that cases and controls come from the same source population, all
patients were recruited from the same hospitals [18]. For each
case, we selected 3 controls, matched by sex, age (65 years),
hospital and point in time. To avoid selection of controls being
associated with exposure to NSAIDs, the controls were recruited
from among patients in preoperative care for scheduled surgical
interventions for non-painful processes such as cataracts, inguinal
or umbilical hernias, and prostate adenomas. The enrolment
criteria of the primary study (cases and controls) excluded patients
who, at the starting date, had a history of cancer, coagulopathy,
Mallory-Weiss syndrome or esophageal varices, and subjects who
were not resident in the study area.
Anti-Anisakis IgE determinations. Prior Anisakis infections
were detected by investigating patient’s sera for the presence of
anti-Anisakis IgE antibodies to the Ani s 1 [19] and Ani s 7 [20]
allergens, which are secretory antigens only produced by the
parasite while the infecting larvae remain alive [21]. The IgE
determinations were by indirect ELISA as previously described
[22]. Briefly, wells in columns 1, 4, 7, and 10 of the 96-well
microtiter plates (Greiner Bio-One, Frickenhausen, Germany)
were filled with 100 ml of phosphate-buffered saline (PBS)
containing rAni s 1 at a concentration of 5 mg/ml, and wells in
columns 2, 5, 8, and 11 were filled with 100 ml of 0.1 M Tris
buffer, pH 10.5, containing 0.6 mg/ml of t-Ani s 7. The wells in
the remaining columns (controls) were filled with PBS alone. After
incubation of the plates at 4uC overnight and washing with Tris-
buffered saline containing 0.2% Tween 20 (TBS-T), the
nonreactive sites were blocked with 200 ml of TBS-T containing
1% of skimmed dry milk (TBS-T1) for 2 h at 37uC. Later, 100 ml
of undiluted serum was added to each well and incubated for 2 h
at 37uC. After a washing step, specific IgE antibodies were
detected by incubation first with 100 ml of a mouse IgE anti-
human mAb (Ingenasa, Madrid, Spain; dilution 1:5000 in TBS-
T1) labeled with fluorescein isothiocyanate (FITC) and afterwards
with 100 ml of peroxidase-conjugated rabbit anti-FITC Ig (Abcam,
Cambridge, England; 1:5000 in TBS-T1). Optical densities (ODs)
at 492 nm were calculated by subtracting the OD value produced
by the same serum in the absence of antigen. Patients displaying
specific IgE antibodies to either of these allergens were classified as
positive. All IgE determinations were performed in duplicate in a
single laboratory.
Anti-Helicobacter pylori IgG determinations. Anti-H.
pylori IgG antibodies were determined in human serum, using a
commercially available ELISA kit (Trinity Biotech Captia, Co.
Wicklaw, Ireland) in accordance with the manufacturer’s protocol.
The choice of this method was based on previous studies, which
reported that serological methods for H. pylori determinations are
not influenced by UGIB [23]. For statistical analysis purposes,
dubious results were deemed negative.
Variable definitions
Qualified, purpose-trained health staff interviewed cases and
controls, after first obtaining written informed consent from the
subjects. Pharmacologic anamnesis was comprehensive. Patients
were first asked about any medications consumed during the two
months prior to admission, and were then presented with a list of
symptoms usually associated with NSAID consumption and asked
whether they had taken any medication for any of these. Finally,
patients who failed to remember the name of any medication were
later telephoned at home to enable them to provide the name.
We defined an NSAID consumer as any subject shown by
pharmacological anamnesis to have consumed some medication
belonging to this therapeutic group in the week preceding the
index date. Subjects taking Acetylsalicylic acid at doses of less than
0.125 g/day (considered to be antiaggregant) were not considered
as NSAIDs consumers. Also, NSAIDs and corticoids administered
by ophthalmic, dermal or rectal route were not deemed to be
exposures.
We calculated a case index date, based on disease course and
symptom-onset dates. For controls, the index date was the date of
the interview. For cases, the consumption of medications between
index and interview dates was not taken into account. Finally, we
reviewed and assessed endoscopy reports of all cases according to
whether or not they described detection of Anisakis larvae in the
stomach or duodenum.
Statistical calculations
We calculated odds ratios (ORs) and their adjusted confidence
intervals (CIs) using hierarchical logistic model through a
generalized linear mixed model [24]. For the purpose of
constructing such models, patients were taken as level one, strata
(each case and their matched controls) as level two, and hospitals
as level three. In the estimation of the models we used the lmer
function, implemented in the context of the lme4 R package
(version 2.7.2) [25]. To construct these models, a bivariate analysis
of each independent variable was performed, and variables with
0.2 in the bivariate analysis were then included in the multivariate
analysis. Independent variables with the highest level of statistical
significance were successively eliminated from the original model,
provided that the coefficients of the principal variables of exposure
changed by no more than 10% and Schwarz’s Bayesian
Information Criterion (BIC) improved [26]. The confidence
intervals of the interaction terms were calculated using the method
Author Summary
Anisakiasis is a worldwide re-emerging disease produced
by the consumption of raw, lightly cooked, smoked or
marinated fish containing live Anisakis larvae. In acute
anisakiasis, mucosal lesions generated by the larvae may
provoke upper gastrointestinal bleeding (UGIB). However,
the effect of past unnoticed Anisakis infections as a risk
factor for UGIB, and a possible synergism with other risk
factors such as NSAIDs intake, have never been investi-
gated. In this case-control study we observed that: i) prior
Anisakis infections and NSAIDs intake are two independent
risk factors for UGIB, and ii) that both risk factors act
synergistically to the extent that their joint effect is 3 times
higher than the sum of their individual effects. We
concluded that, in countries where Anisakis infections are
frequent, it would be wise to determine parasite-specific
IgE antibodies and to conduct a closer follow-up of
patients who consume raw or lightly cooked fish and who
are prescribed NSAIDs for long periods.
Anisakis, NSAIDs and UGIB
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linear mixed model were validated by comparing them against
results from comparable models obtained by running conditional
logistic regression. We calculated the ratio of the combined effects
to the sum of the separate effects of Anisakis and NSAID (S) (along
with its 95% confidence interval) [28] as a measure of additive
interaction, [18] since S has been shown to be the most reliable
measure of additive interaction when adjusting for confounding
[29].
Ethics statement
The study protocol was approved by the following ethics
committees: i) Comite ´ Etico de Investigacio ´n Clı ´nica de Galicia; ii)
Comite ´ Etico de Investigacio ´n Clı ´nica de la Universidad de
Valladolid; and iii) Comite ´ Etico de Investigacio ´n Clı ´nica del
Hospital de Galdakao-Usansolo. All cases and controls were
required to give written informed consent, and where such
approval was not forthcoming, the subject concerned was
excluded from the study.
Results
Sera from 215 cases and 650 controls were available for the
study. The clinical signs most frequently presented by cases were:
dizziness (58.1%); black vomitus and/or vomiting of blood
(40.5%), and melena (19%). With regard to controls, most of
patients were recruited from the pre-operative unit for minor
surgical procedures: 295 (45.4%) for cataracts, and 168 (25.8%) for
inguinal hernias. The demographic and clinical characteristics of
cases and controls are listed in Table 1.
The results showed that 54 (25.1%) cases and 100 (15.4%)
controls were positive for Anisakis (Ani s 1 or Ani s 7), while 73
(33.9%) cases and 76 (11.7%) controls were NSAID consumers
(Table 2). Considering IgE determinations in cases plus controls,
85 subjects (55.2%) were seropositive for Ani 1 plus Ani s 7, 40
subjects (25.9%) positive for only Ani s 1, and 29 subjects (18.8%)
positive for only Ani s 7. As regards cases, 30 (55.5%) patients were
positive for both allergens, 16 (29.6%) patients were positive for
only Ani s 1 and 8 (14.8%) patients were positive for only Ani s 7.
In the control group 55 (55.0%) subjects were positive for both
allergens, 24 (24.0%) subjects were positive for only Ani s 1 and 21
(21.0%) subjects were positive for only Ani s 7. With regard to sex
distribution in Anisakis seropositive patients (either for Ani s 1 or
Ani s 7 allergens), 35 cases (64.8%) and 76 controls (76.0%) were
male.
To investigate the effects of the interaction between Anisakis
simplex IgE sensitization and NSAID intake on risk of UGIB, we
calculated the ORs values obtained for both variables with and
without interactions. The results in Table 2, model 1, show the
ORs values without interactions. Anisakis seropositive subjects
registered a 1.74 fold higher risk of suffering from UGIB than
seronegative subjects (95% CI: 1.13–2.69). However, when the
effect of prior Anisakis infections was stratified by NSAID
consumption (Table 2, model 2), we observed that this had no
effect among non-consumers of NSAIDs (OR=1.46, [95%CI:
(0.87–2.43]), but that there was a more than 14-fold higher risk of
UGIB (OR=14.45 [95% CI: 6.46–32.33]) among NSAID
consumers than in Anisakis-negative non-consumers of NSAIDs.
The interaction was additive, with a synergistic index of 3.01 (95%
CI: 1.18–7.71). Applying conditional logistic regression to these
analyses provided very similar ORs, but with wider 95%CI range.
The data in Table 3 show the location and type of
gastrointestinal lesions observed by endoscopy in cases, with
respect to Anisakis sensitization and NSAIDs intake. There were no
differences in the number and location of bleeding lesions between
Anisakis sensitized patients, NSAIDs consumers, or patients lacking
these risk factors. In addition, the endoscopic reports revealed a
single case of acute anisakiasis. This corresponded to a 53-year-old
female with three Anisakis larvae penetrating two gastric ulcers
located in the fornix region of the stomach. The patient presented
with hematemesis accompanied by dyspepsia and pyrosis, and was
seropositive for Ani s 1 and Ani s 7 allergens.
Discussion
This is the first epidemiological study showing that: i) prior
Anisakis infections causing IgE sensitization are an independent risk
factor for UGIB (with an almost twofold increase in the risk) and ii)
that this effect is modified by NSAID consumption, to the extent
that the risk of UGIB can increase by more than 14 times through
a synergic effect between Anisakis and NSAIDs, showing in turn
that the joint effect of the two risk factors is 3 times higher than the
sum of their individual effects.
Table 1. Demographic, comorbid conditions and medication
used in patients included in the case and control groups.
Cases
(n=215)
Controls
(n=650)
Demographics
Men, no.(%) 157 (73.0) 465 (71.5)
Age, mean (SD) 65.0 (616.2) 63.4 (615.6)
Comorbid conditions (%)
Gastric ulcer* 40 (18.6) 45 (6.9)
Duodenal ulcer* 28 (13.0) 24 (3.7)
Unspecific ulcer* 0 (0.0) 3 (0.5)
Diabetes mellitus 27 (12.6) 89 (13.7)
Depression 38 (17.7) 112 (17.2)
Heart disease 62 (28.8) 133 (20.5)
Hypertension 81 (37.7) 234 (36.0)
Hypercholesterolemia 76 (35.3) 195 (30.0)
Arthrosis 59 (27.4) 190 (29.2)
Arthritis 16 (7.4) 40 (6.2)
Osteoporosis 11 (5.1) 31 (4.7)
Hepatic disease 12 (5.6) 59 (9.1)
Helicobacter pylori 201 (93.5) 549 (84.5)
Tobacco dependence 40 (18.6) 130 (20.0)
Alcohol
No consumption 77 (35.8) 249 (38.3)
Low 83 (38.6) 269 (41.4)
Moderate 42 (19.5) 115 (17.7)
Heavy 13 (6.0) 17 (2.6)
Medication
Drugs, Mean (SD) 3.90 (62.6) 2.98 (62.4)
NSAIDs, no. (%) 73 (34.0) 76 (11.7)
PPI, no. (%) 23 (10.7) 82 (12.6)
Antiplatelet drugs, no. (%) 50 (23.3) 94 (14.5)
Oral anticoagulants, no. (%) 19 (8.8) 35 (5.4)
Selective serotonin reuptake inhibitors, no. (%) 15 (7.0) 40 (6.2)
(*): Antecedent not directly related with current illness.
doi:10.1371/journal.pntd.0001214.t001
Anisakis, NSAIDs and UGIB
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control group) tested positive for Ani s 1 or Ani s 7 allergens.
However, the results appear to be accurate because the combined
Ani s 1 and Ani s 7 ELISAs used in this study are highly sensitive
and specific in comparison with other serological methods [22].
The present results are also consistent with previous reports
[15,16] showing an extremely high seroprevalence for IgE
antibodies to this parasite in the northern, central, and southern
regions of Spain, where positive IgE values are observed in more
than 10% of the population. Futhermore, other results showing
that seropositive patients always had a prior history of ingestion of
raw or undercooked fish [5] exclude the possibility that these high
values were due to recognition of cross-reacting allergens present
in other organisms such as mites [30]. Anisakis infections in Spain
are mainly related to the ingestion of boquerones en vinagre _pickled
anchovies_ [4,5], although infections caused by eating under-
cooked fish (e.g. hake) have also been reported [4,15,31].
The presence of IgE antibodies in serum against specific
secretory Anisakis allergens as Ani s 7, and probably Ani s 1, reveals
that the patient has suffered one or more previous infections by
this parasite [32]. However, for correct interpretation of the
results, the effect of currently active and past Anisakis infections
should be considered separately. In patients with active gastric
anisakiasis, some of them may suffer erosions or hemorrhagic
lesions of the mucosa, which can be detected by gastroscopy [4].
Bleeding during this phase can be explained by several causes,
including: a) the marked inflammatory allergic status of the
mucosa, accompanied by massive infiltration of eosinophils,
neutrophils, macrophages and lymphocytes in response to parasite
excretory antigens [33]; b) the direct erosive action of larvae
moving into the gastric mucosa [34]; and c) the activity of
proteases [35] and anticoagulant [36] substances released by the
parasite.
In a recent study [22] we have observed that about 94% and
61% of symptomatic patients sensitized to Anisakis antigens have
IgE antibodies to the Ani s 7 and Ani s 1 allergens, respectively.
However, for patients that recognized both allergens the response
to Ani s 1 was more prolonged in time. The data in the present
study, showing that a considerable proportion of sera (25.9%) were
only positive to the Ani s 1 allergen, suggest that many positive IgE
results are due to past, unnoticed, Anisakis infections. In addition, it
was reported that gastric Anisakis infections are much more
frequent than duodenal anisakiasis [37]. The similar number of
bleeding ulcerous lesions observed in our study at gastric and
duodenal level, and the fact that only one positive case of active
anisakiasis was detected by endoscopy, also suggest that the
increased risk of UGIB in Anisakis seropositive patients is not due
to active infections.
Unlike active anisakiasis, the implication of past Anisakis
infections as a risk factor for UGIB is less evident. One could
hypothesize, however, that effector molecules produced by defense
cells previously activated in the GI tract in response to allergens
Table 2. Odds ratios for upper gastrointestinal bleeding associated with NSAIDs and Anisakis, and their interaction.
Independent variables Cases Controls
Adjusted
OR (95% CI)* Synergistic Index (95% CI)
MODEL 1: Model without interactions ----
NSAIDs 73 76 5.80 (3.82–8.82)
Anisakis 54 100 1.74 (1.13–2.69)
MODEL 2: Interaction between NSAIDs and Anisakis 3.01 (1.18–7.71)
NSAID non-consumers
Anisakis-negative 109 485 1.00
Anisakis-positive 33 89 1.46 (0.87–2.43)
NSAID consumers
Anisakis-negative 52 65 5.01 (3.14–8.01)
Anisakis-positive 21 11 14.45 (6.46–32.33)
(*): Adjusted for past history of GI disorders, proton pump inhibitors, antiplatelet drugs, oral anticoagulants, reliability of interview.
doi:10.1371/journal.pntd.0001214.t002
Table 3. Type and location of endoscopic lesions observed in cases with respect to Anisakis sensitization and NSAIDs intake.
Type and location of lesions
Anisakis
n=54
NSAIDs
n=73
NSAIDs plus
Anisakis
n=21
NSAIDs or
Anisakis
n=85
None
n=109
Erosions
Gastric 15 (27.8) 21 (28.8) 3 (14.3) 30 (35.3) 32 (29.4)
Duodenal 8 (14.8) 9 (12.3) 2 (9.5) 13 (15.3) 12 (11.0)
Ulcers
Gastric 19 (35.2) 31 (42.4) 9 (42.9) 32 (37.6) 41 (37.6)
Duodenal 27 (50.0) 35 (47.9) 11 (52.4) 39 (45.9) 47 (43.1)
The numbers between parenthesis show the corresponding percentages.
doi:10.1371/journal.pntd.0001214.t003
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www.plosntds.org 4 June 2011 | Volume 5 | Issue 6 | e1214and other Anisakis antigens, might provoke mucosal injury acting
either alone or synergistically with other noxious factors present,
such as NSAIDs. Candidate cells for mediating such action are
eosinophils and, perhaps other pro-inflammatory cells that remain
infiltrating the granulomatous tissue around the infecting larvae,
or its debris, for long periods [37]. In particular, eosinophils are GI
primary resident cells [38] which reportedly have immunoregu-
latory roles [39] and act as antigen-presenting cells in response to
intestinal nematodes [40], and the cytotoxic preformed cationic
proteins that they produce upon activation are able to cause
mucosal damage, as seen in some intestinal inflammatory diseases
[41,42]. Eosinophils have also been reported to be present in the
granulation tissue of perforated gastric ulcers in Japan, the country
where Anisakis infections are most frequent, and the degree of
infiltration by these cells was suggested to be a marker of
perforation risk [43]. In this sense, it is thought that the matrix
metalloproteinase-1 expressed in the cytoplasm of eosinophils may
be able to digest collagen types I and III, which compose the
stomach wall, and thus contribute to ulcer perforation [44].
Interestingly, NSAIDs also stimulate eosinophil production by
downregulating PGE2 synthesis and upregulating production of
cysteinyl leukotrienes [45] suggesting that the biochemical
mechanisms whereby both risk factors potentiate UGIB may be
interconnected.
As in Anisakis infections, it can be hypothesized that other
infectious agents causing chronic infections of the upper
gastrointestinal tract such as Helicobacter pylori, or food hypersen-
sitivity [46], may also modify the risk of UGIB in NSAID
consumers. In the present study, the observed synergism between
NSAID consumption and prior Anisakis infections on the risk of
UGIB were obtained from data adjusted by seroprevalence to H.
pylori, thus discounting any possible bias caused by this
confounding variable. Likewise, for food hypersensitivity to have
a confounding effect there would have to be a positive correlation
between food allergy and exposure to NSAIDs or infection by
Anisakis larvae. However, this is not the case because there is no
reason to think that subjects with food allergy may be more likely
to consume NSAIDs or to be infected by the parasite.
Finally, it shoud be noted that because of the low prevalence of
consumption of the individual NSAIDs in the sample, the
individual effect of the interaction of each particular NSAID with
Anisakis could not be observed. Nonetheless, since all NSAIDs
share the same mechanism of action, it is expected that all act
synergistically with Anisakis to a greater or lesser extent.
From the results of the present study we concluded that, in
countries where there is a suspected presence of Anisakis infection,
it would be wise to confirm whether or not the patient has a history
of ingesting raw or undercooked fish before prescribing NSAIDs
for long periods. For patients giving a positive response to this
query, we recommend performing a parasite-specific IgE deter-
mination and conducting a closer follow-up during treatment with
NSAIDs when the test is positive.
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